MSFrontier

OzEAN

Ozanimod (Zeposia®) In Patients With RRMS: A 3-Year, Multicenter, Prospective, Non-Interventional Study to Document Utilization, Effectiveness and Quality of Life in Clinical Practice in Germany (OZEAN)
CompletedRelapsing MSNCT05335031

We could not find results for this trial

I know where the results are

What it found

No result found

We found no results in the registry or in papers.

This trial finished 16 months ago. We found no results in the registry or in any paper that cites it.

What was tested

Treatment tested

  • Ozanimod

    Sphingosine 1-phosphate receptor 5 modulator

What it measured

Main measures

  • Proportion of participants persistence with therapy

    Up to 36 months

Other measures (29)

  • Distribution of participant demographics characteristics: Age

    At baseline

  • Distribution of participant demographics characteristics: Sex

    At baseline

  • Distribution of participant demographics characteristics: Height

    At baseline

  • Distribution of participant demographics characteristics: Body weight

    At baseline

  • Distribution of clinical characteristics: Smoking status

    At baseline

  • Distribution of clinical characteristics: Multiple Sclerosis (MS) diagnosis

    At baseline

  • Distribution of clinical characteristics: MS anamnesis/history

    At baseline

  • Distribution of clinical characteristics: Prior diseases

    At baseline

  • Distribution of clinical characteristics: Concomitant diseases

    At baseline

  • Distribution of clinical characteristics: Concomitant medication

    At baseline

Who could take part

Relapsing MS · 18 and over

Inclusion Criteria: * Confirmed diagnosis of relapsing-remitting multiple sclerosis (RRMS) * The decision upon treatment with ozanimod must have been made before enrollment and independently of this non-interventional observational study * All data on ozanimod treatment are collected prospectively. The retrospective documentation of ozanimod therapy and enrollment of participants that are already on ozanimod therapy is not allowed Exclusion Criteria: * Special warnings, precautions and contraindications specified in the current version of the Summary of Product Characteristics (SmPC) * Hypersensitivity to the active substance(s) or to any of the excipients of ozanimod as specified in the prescribing information must not be enrolled * Participation in any other clinical studies Other protocol-defined inclusion/exclusion criteria apply

As registered. Criteria can change, so ask the trial team or your neurologist.

About this trial

In the sponsor's words

The purpose of this study is to collect real-world data and to gain insights about long-term usage of ozanimod (Zeposia ®), its effect on well-defined outcome parameters comprising participant-relevant outcomes, as well as quality of life, effectiveness, and incidence of adverse events.

Papers

Loading reviews and guidelines…

Related trials

History

    1. Started

      Mar 2021

    2. Main results due

      Jun 2025

    3. Finished

      Jun 2025

    Assembled by software from public sources and not checked by people. Each record links to its source. Report an error